Altre lingue Hansa Biopharma AB Börse Stuttgart

Azioni

24H

SE0002148817

Mercato chiuso - Börse Stuttgart Altri mercati azionari 11:17:24 21/06/2024			Variaz. 5gg	Var. 1 gen.
3,684 ^EUR	+1,71%		-10,80%	+57,17%

31/05	Hansa Biopharma termina la randomizzazione dei pazienti per l'uso di Imlifidase nello studio sul trapianto di rene	MT
31/05	Hansa Biopharma completa la randomizzazione nello studio pivotale di fase 3 Usa Confides	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm	07/06
Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial	31/05
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial	31/05
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial	31/05
Notice to Annual General Meeting in Hansa Biopharma AB (publ)	27/05
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting	21/05
Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting	21/05
Correction, Hansa Biopharma, increase in number of shares and votes	06/05
Correction: Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma Q1 - Improved European launch support	19/04
Hansa Biopharma interim report January-March 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03
Hansa Biopharma Hires New CFO	22/02
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hansa Biopharma AB Börse Stuttgart

Azioni

24H

SE0002148817

Altre lingue

Filtri